Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications
Tóm tắt
Từ khóa
Tài liệu tham khảo
Amidon, 1995, A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharmaceutical Research, 12, 413, 10.1023/A:1016212804288
Artursson, 2001, Caco-2 monolayers in experimental and theoretical predictions of drug transport, Advanced Drug Delivery Reviews, 46, 27, 10.1016/S0169-409X(00)00128-9
Atkinson, 1962, Effect of particle size on blood griseofulvin-levels in man, Nature, 193, 588, 10.1038/193588a0
Avdeef, 2007, Solubility of sparingly-soluble ionizable drugs, Advanced Drug Delivery Reviews, 59, 568, 10.1016/j.addr.2007.05.008
Badawy, 2006, Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389, Pharmaceutical Research, 23, 989, 10.1007/s11095-006-9899-z
Badawy, 2007, Microenvironmental pH modulation in solid dosage forms, Journal of Pharmaceutical Sciences, 96, 948, 10.1002/jps.20932
Bak, 2008, The co-crystal approach to improve the exposure of a water-insoluble compound: AMG 517 sorbic acid co-crystal characterization and pharmacokinetics, Journal of Pharmaceutical Sciences, 97, 3942, 10.1002/jps.21280
Blagden, 2007, Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates, Advanced Drug Delivery Reviews, 59, 617, 10.1016/j.addr.2007.05.011
Brewster, 2007, Cyclodextrins as pharmaceutical solubilizers, Advanced Drug Delivery Reviews, 59, 645, 10.1016/j.addr.2007.05.012
Chen, 2004, Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68, International Journal of Pharmaceutics, 286, 69, 10.1016/j.ijpharm.2004.08.009
Chiba, 1991, Improvement of dissolution and bioavailability for mebendazole, an agent for human echinococcosis, by preparing solid dispersion with polyethylene glycol, Chemical & Pharmaceutical Bulletin, 39, 2158, 10.1248/cpb.39.2158
Childs, 2007, The salt-cocrystal continuum: the influence of crystal structure on ionization state, Molecular Pharmaceutics, 4, 323, 10.1021/mp0601345
Chiou, 1971, Pharmaceutical applications of solid dispersion systems, Journal of Pharmaceutical Sciences, 60, 1281, 10.1002/jps.2600600902
Cook, 2008, Application of the biopharmaceutical classification system in clinical drug development—an industrial view, The AAPS Journal, 10, 306, 10.1208/s12248-008-9036-5
Dannenfelser, 2004, Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol-polysorbate 80 solid dispersion carrier system, Journal of Pharmaceutical Sciences, 93, 1165, 10.1002/jps.20044
EMEA, 2010. Guideline on the investigation of bioequivalence. Avaiable at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf (Last accessed 13 April 2011).
Fakes, 2009, Enhancement of oral bioavailability of an HIV-attachment inhibitor by nanosizing and amorphous formulation approaches, International Journal of Pharmaceutics, 370, 167, 10.1016/j.ijpharm.2008.11.018
Fasano, 1998, Innovative strategies for the oral delivery of drugs and peptides, Trends in Biotechnology, 16, 152, 10.1016/S0167-7799(97)01170-0
FDA, 2000. Guidance for Industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070246.pdf (Last accessed 13 April 2011).
Fukushima, 2007, Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system, Biological & Pharmaceutical Bulletin, 30, 733, 10.1248/bpb.30.733
Galia, 1999, Albendazole generics—a comparative in vitro study, Pharmaceutical Research, 16, 1871, 10.1023/A:1018907527253
Gimenez, 2004, Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins, Journal of Acquired Immune Deficiency Syndrome, 36, 649, 10.1097/00126334-200406010-00001
Gursoy, 2004, Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs, Biomedicine & Pharmacotherapy, 58, 173, 10.1016/j.biopha.2004.02.001
Guzman, 2007, Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations, Journal of Pharmaceutical Sciences, 96, 2686, 10.1002/jps.20906
Hanafy, 2007, Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug, Advanced Drug Delivery Reviews, 59, 419, 10.1016/j.addr.2007.04.005
Hancock, 2000, What is the true solubility advantage for amorphous pharmaceuticals?, Pharmaceutical Research, 17, 397, 10.1023/A:1007516718048
He, 2010, Microemulsions as drug delivery systems to improve the solubility and the bioavailability of poorly water-soluble drugs, Expert Opinion on Drug Delivery, 7, 445, 10.1517/17425241003596337
He, 2010, Comparison of spray freeze drying and the solvent evaporation method for preparing solid dispersions of baicalein with pluronic F68 to improve dissolution and oral bioavailability, AAPS PharmSciTech
Hecq, 2006, Preparation and in vitro/in vivo evaluation of nano-sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed poorly water-soluble weak base, European Journal of Pharmaceutics and Biopharmaceutics, 64, 360, 10.1016/j.ejpb.2006.05.008
Horter, 2001, Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract, Advanced Drug Delivery Reviews, 46, 75
Huang, 2004, Impact of solid state properties on developability assessment of drug candidates, Advanced Drug Delivery Reviews, 56, 321, 10.1016/j.addr.2003.10.007
Jamzad, 2006, Role of surfactant and pH on dissolution properties of fenofibrate and glipizide—a technical note, AAPS PharmSciTech, 7, E33, 10.1208/pt070233
Jia, 2002, Effect of nanonization on absorption of 301029: ex vivo and in vivo pharmacokinetic correlations determined by liquid chromatography/mass spectrometry, Pharmaceutical Research, 19, 1091, 10.1023/A:1019829622088
Jia, 2003, Carbendazim: disposition, cellular permeability, metabolite identification, and pharmacokinetic comparison with its nanoparticle, Journal of Pharmaceutical Sciences, 92, 161, 10.1002/jps.10272
Jinno, 2006, Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs, Journal of Controlled Release, 111, 56, 10.1016/j.jconrel.2005.11.013
Jinno, 2008, In vitro–in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol, Journal of Controlled Release, 130, 29, 10.1016/j.jconrel.2008.05.013
Joshi, 2004, Bioavailability enhancement of a poorly water-soluble drug by solid dispersion in polyethylene glycol-polysorbate 80 mixture, International Journal of Pharmaceutics, 269, 251, 10.1016/j.ijpharm.2003.09.002
Jounela, 1975, Effect of particle size on the bioavailability of digoxin, European Journal of Clinical Pharmacology, 8, 365, 10.1007/BF00562664
Jung, 2010, Bioavailability of indomethacin-saccharin cocrystals, The Journal of Pharmacy and Pharmacology, 62, 1560, 10.1111/j.2042-7158.2010.01189.x
Kai, 1996, Oral absorption improvement of poorly soluble drug using solid dispersion technique, Chemical & Pharmaceutical Bulletin, 44, 568, 10.1248/cpb.44.568
Kaushal, 2004, Amorphous drug delivery systems: molecular aspects, design, and performance, Critical Reviews in Therapeutic Drug Carrier System, 21, 133, 10.1615/CritRevTherDrugCarrierSyst.v21.i3.10
Kawabata, 2010, Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability, European Journal of Pharmaceutical Sciences, 39, 256, 10.1016/j.ejps.2009.12.009
Kennedy, 2008, Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study, Molecular Pharmaceutics, 5, 981, 10.1021/mp800061r
Kesisoglou, 2007, Nanosizing—oral formulation development and biopharmaceutical evaluation, Advance Drug Delivery Review, 59, 631, 10.1016/j.addr.2007.05.003
Kohli, 2010, Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability, Drug Discovery Today, 15, 958, 10.1016/j.drudis.2010.08.007
Kohri, 1999, Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique, The Journal of Pharmacy and Pharmacology, 51, 159, 10.1211/0022357991772277
Kondo, 1994, Improved oral absorption of enteric coprecipitates of a poorly soluble drug, Journal of Pharmaceutical Sciences, 83, 566, 10.1002/jps.2600830425
Kondo, 1993, Improved oral absorption of a poorly water-soluble drug, HO-221, by wet-bead milling producing particles in submicron region, Chemical & Pharmaceutical Bulletin, 41, 737, 10.1248/cpb.41.737
Kranz, 2005, Development of a single unit extended release formulation for ZK 811 752, a weakly basic drug, European Journal of Pharmaceutical Sciences, 26, 47, 10.1016/j.ejps.2005.04.018
Ku, 2008, Use of the biopharmaceutical classification system in early drug development, The AAPS Journal, 10, 208, 10.1208/s12248-008-9020-0
Ku, 2010, A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept, Pharmaceutical Development & Technology, 1
Kubo, 2009, Enhanced bioavailability of probucol following the administration of solid dispersion systems of probucol-polyvinylpyrrolidone in rabbits, Biological & Pharmaceutical Bulletin, 32, 1880, 10.1248/bpb.32.1880
Kushida, 2002, Improvement of dissolution and oral absorption of ER-34122, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion, Journal of Pharmaceutical Sciences, 91, 258, 10.1002/jps.10020
Lakshman, 2008, Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug, Molecular Pharmaceutics, 5, 994, 10.1021/mp8001073
Law, 2004, Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations, Journal of Pharmaceutical Sciences, 93, 563, 10.1002/jps.10566
Li, 2005, Investigation of solubility and dissolution of a free base and two different salt forms as a function of pH, Pharmaceutical Research, 22, 628, 10.1007/s11095-005-2504-z
Lipinski, 2000, Drug-like properties and the causes of poor solubility and poor permeability, Journal of Pharmacological and Toxicological Methods, 44, 235, 10.1016/S1056-8719(00)00107-6
Lipinski, 2001, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Advanced Drug Delivery Reviews, 46, 3, 10.1016/S0169-409X(00)00129-0
Liu, 2006, Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate, Drug Development and Industrial Pharmacy, 32, 115, 10.1080/03639040500388573
Liversidge, 1995, Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs, International Journal of Pharmaceutics, 125, 91, 10.1016/0378-5173(95)00122-Y
Lobenberg, 2000, Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards, European Journal of Pharmaceutics and Biopharmaceutics, 50, 3, 10.1016/S0939-6411(00)00091-6
Loftsson, 1996, Pharmaceutical applications of cyclodextrins. 1: Drug solubilization and stabilization, Journal of Pharmaceutical Sciences, 85, 1017, 10.1021/js950534b
Müller, 1998, Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique, International Journal of Pharmaceutics, 160, 229, 10.1016/S0378-5173(97)00311-6
McNamara, 2006, Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API, Pharmaceutical Research, 23, 1888, 10.1007/s11095-006-9032-3
Mosharraf, 1995, The effect of particle size and shape on the surface specific dissolution rate of microsized practically insoluble drugs, International Journal of Pharmaceutics, 122, 35, 10.1016/0378-5173(95)00033-F
Mueller, 1994, Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation, Pharmaceutical Research, 11, 301, 10.1023/A:1018923912135
Newa, 2008, Enhancement of solubility, dissolution and bioavailability of ibuprofen in solid dispersion systems, Chemical & Pharmaceutical Bulletin, 56, 569, 10.1248/cpb.56.569
Ni, 2002, Solubilization and preformulation of carbendazim, International Journal of Pharmaceutics, 244, 99, 10.1016/S0378-5173(02)00318-6
Onoue, 2010, Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach, International Journal of Pharmaceutics, 399, 94, 10.1016/j.ijpharm.2010.08.007
Onoue, 2010, Formulation design and photochemical studies on nanocrystal solid dispersion of curcumin with improved oral bioavailability, Journal of Pharmaceutical Sciences, 99, 1871, 10.1002/jps.21964
Onoue, 2011, Development of high-energy amorphous solid dispersion of nanosized nobiletin, a citrus polymethoxylated flavone, with improved oral bioavailability, Journal of Pharmaceutical Sciences, 100, 3793, 10.1002/jps.22585
Pudipeddi, 2005, Trends in solubility of polymorphs, Journal of Pharmaceutical Sciences, 94, 929, 10.1002/jps.20302
Rajewski, 1996, Pharmaceutical applications of cyclodextrins. 2: In vivo drug delivery, Journal of Pharmaceutical Sciences, 85, 1142, 10.1021/js960075u
Rodriguez-Spong, 2004, General principles of pharmaceutical solid polymorphism: a supramolecular perspective, Advanced Drug Delivery Reviews, 56, 241, 10.1016/j.addr.2003.10.005
Scholz, 2002, Influence of hydrodynamics and particle size on the absorption of felodipine in labradors, Pharmaceutical Research, 19, 42, 10.1023/A:1013651215061
Schultheiss, 2009, Pharmaceutical cocrystals and their physicochemical properties, Crystal Growth Design, 9, 2950, 10.1021/cg900129f
Serajuddin, 2007, Salt formation to improve drug solubility, Advanced Drug Delivery Reviews, 59, 603, 10.1016/j.addr.2007.05.010
Shegokar, 2010, Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives, International Journal of Pharmaceutics, 399, 129, 10.1016/j.ijpharm.2010.07.044
Sinha, 2010, Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir, AAPS PharmSciTech, 11, 518, 10.1208/s12249-010-9404-1
Stella, 2007, Prodrug strategies to overcome poor water solubility, Advance Drug Delivery Review, 59, 677, 10.1016/j.addr.2007.05.013
Stephenson, 2011, Physical stability of salts of weak bases in the solid-state, Journal of Pharmaceutical Sciences, 100, 1607, 10.1002/jps.22405
Streubel, 2000, pH-independent release of a weakly basic drug from water-insoluble and -soluble matrix tablets, Journal of Controlled Release, 67, 101, 10.1016/S0168-3659(00)00200-5
Sugano, 2003, Prediction of human intestinal permeability using artificial membrane permeability, International Journal of Pharmaceutics, 257, 245, 10.1016/S0378-5173(03)00161-3
Sun, 2008, Nimodipine semi-solid capsules containing solid dispersion for improving dissolution, International Journal of Pharmaceutics, 359, 144, 10.1016/j.ijpharm.2008.03.040
Sylvestre, 2011, Nanonization of megestrol acetate by laser fragmentation in aqueous milieu, Journal of Controlled Release, 149, 273, 10.1016/j.jconrel.2010.10.034
Takagi, 2006, A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan, Molecular Pharmaceutics, 3, 631, 10.1021/mp0600182
Tatavarti, 2006, Microenvironmental pH modulation based release enhancement of a weakly basic drug from hydrophilic matrices, Journal of Pharmaceutical Sciences, 95, 1459, 10.1002/jps.20612
Thanou, 2001, Chitosan and its derivatives as intestinal absorption enhancers, Advanced Drug Delivery Reviews, 50, S91, 10.1016/S0169-409X(01)00180-6
Tonnesen, 2002, Studies of curcumin and curcuminoids, XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability, International Journal of Pharmaceutics, 244, 127, 10.1016/S0378-5173(02)00323-X
Tran, 2010, Dissolution-modulating mechanism of pH modifiers in solid dispersion containing weakly acidic or basic drugs with poor water solubility, Expert Opinion on Drug Delivery, 7, 647, 10.1517/17425241003645910
Van Eerdenbrugh, 2009, Itraconazole/TPGS/Aerosil200 solid dispersions: characterization, physical stability and in vivo performance, European Journal of Pharmaceutical Sciences, 38, 270, 10.1016/j.ejps.2009.08.002
Vasconcelos, 2007, Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs, Drug Discovery Today, 12, 1068, 10.1016/j.drudis.2007.09.005
Vaughn, 2006, Supersaturation produces high bioavailability of amorphous danazol particles formed by evaporative precipitation into aqueous solution and spray freezing into liquid technologies, Drug Development and Industrial Pharmacy, 32, 559, 10.1080/03639040500529176
Volpe, 2008, Variability in Caco-2 and MDCK cell-based intestinal permeability assays, Journal of Pharmaceutical Sciences, 97, 712, 10.1002/jps.21010
Wahlang, 2011, Identification of permeability-related hurdles in oral delivery of curcumin using the Caco-2 cell model, European Journal of Pharmaceutics and Biopharmaceutics, 77, 275, 10.1016/j.ejpb.2010.12.006
WHO, 2006. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Annex. 7, WHO Technical Report Series 937. Available at: http://whqlibdoc.who.int/trs/WHO_TRS_937_eng.pdf (Last accessed 13 April 2011).
Wu, 2005, Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system, Pharmaceutical Research, 22, 11, 10.1007/s11095-004-9004-4
Wu, 2004, The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human, International Journal of Pharmaceutics, 285, 135, 10.1016/j.ijpharm.2004.08.001
Xia, 2010, Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats, Pharmaceutical Research, 27, 1965, 10.1007/s11095-010-0200-0
Yamashita, 2003, Establishment of new preparation method for solid dispersion formulation of tacrolimus, International Journal of Pharmaceutics, 267, 79, 10.1016/j.ijpharm.2003.07.010
Yoshizuka, 1996, Selective separation of flavonoids with a polyvinyl alcohol membrane, Journal of Membrane Science, 118, 41, 10.1016/0376-7388(96)00075-0
Zerrouk, 2001, In vitro and in vivo evaluation of carbamazepine-PEG 6000 solid dispersions, International Journal of Pharmaceutics, 225, 49, 10.1016/S0378-5173(01)00741-4
Zhang, 2007, Efficient co-crystal screening using solution-mediated phase transformation, Journal of Pharmaceutical Sciences, 96, 990, 10.1002/jps.20949
Zhang, 2004, Phase transformation considerations during process development and manufacture of solid oral dosage forms, Advanced Drug Delivery Reviews, 56, 371, 10.1016/j.addr.2003.10.009